Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial

Precision BioSciences Inc (NASDAQ:DTIL) and SpringWorks Therapeutics Inc (NASDAQ:SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.
In the study, Precision's investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks' investigational gamma-secretase inhibitor in relapsed/refractory multiple myeloma.
The Company will share interim monotherapy data for PBCAR269A later this year and conduct IND enabling studies to advance PBCAR269B, an immune-evading, stealth cell formulation, into the clinic in 2022.
Price Action: DTIL shares are up 14.6% at $13.05 during the premarket session on the last check Monday.